8-K: KALA BIO Announces Second Quarter 2024 Financial Results and Provides Corporate Update

KALA BIO reported its second quarter 2024 financial results, highlighted by a $12.5 million private placement and progress in clinical trials for its lead candidate, KPI-012.

Summary

• KALA BIO announced its financial results for the second quarter ended June 30, 2024, and provided a corporate update.
• The company completed a $12.5 million private placement financing led by SR One, with participation from ADAR1 Capital Management and another life sciences-focused investor.
• KALA BIO's cash resources totaled $54.2 million as of June 30, 2024, and are expected to fund operations into the fourth quarter of 2025, including anticipated funding from a CIRM award.
• Topline data from the Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) is targeted for release in the first quarter of 2025.
• The company is also exploring the potential of KPI-012 for additional rare, front-of-the-eye diseases, including Limbal Stem Cell Deficiency (LSCD).
• KALA BIO is evaluating its second asset, KPI-014, for the treatment of rare, inherited retinal diseases such as Retinitis Pigmentosa and Stargardt Disease.
• For the quarter ended June 30, 2024, the net loss was $9.6 million, or $3.16 per share, compared to a net loss of $10.4 million, or $4.36 per share, for the same period in 2023.
• For the six months ended June 30, 2024, the net loss was $21.4 million, or $7.32 per share, compared to a net loss of $24.9 million, or $11.15 per share, for the same period in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful private placement, extended cash runway, and progress in clinical trials. However, the ongoing losses and inherent risks in drug development temper the overall optimism.

Positives

• The $12.5 million private placement strengthens KALA BIO's financial position.
• The company's cash runway extends into the fourth quarter of 2025, providing financial stability.
• Progress is being made in the clinical development of KPI-012, with topline data expected in early 2025.
• KALA BIO is exploring multiple indications for its MSC-S platform, increasing its potential market reach.
• The net loss per share decreased compared to the same periods in the previous year.

Negatives

• The company reported a net loss of $9.6 million for the second quarter of 2024.
• The company reported a net loss of $21.4 million for the first six months of 2024.
• Research and development expenses increased for both the quarter and six-month periods compared to 2023.

Risks

• The company's ability to comply with the requirements under the CIRM award is a risk.
• There are uncertainties inherent in the initiation and conduct of preclinical studies and clinical trials.
• The availability and timing of data from clinical trials are uncertain.
• There is a risk that results of early clinical trials may not be indicative of future trial results.
• Regulatory review of clinical trials and marketing approvals are uncertain.
• The company's ability to retain and hire key personnel is a risk.
• The company's ability to comply with covenants under its loan agreement is a risk.
• The company may need additional financing in the future.

Future Outlook

KALA BIO anticipates that its current cash resources, along with anticipated funding from the CIRM award, will enable it to fund operations into the fourth quarter of 2025. The company is targeting topline results from the Phase 2b CHASE trial in the first quarter of 2025 and plans to explore additional indications for its MSC-S platform.

Management Comments

• Mark Iwicki, Chair and Chief Executive Officer of KALA BIO, stated that the company is well-positioned to advance KPI-012 toward a late-stage clinical readout.
• Mr. Iwicki also mentioned the company's aim to explore the broad potential of its MSC-S platform to produce innovative therapies for rare and severe eye diseases.
• Mr. Iwicki believes KPI-012 represents an exciting pipeline-in-a-product opportunity to address multiple severe corneal diseases.

Industry Context

This announcement is relevant to the biopharmaceutical industry, particularly companies focused on developing therapies for rare and severe eye diseases. The progress of KPI-012 and the exploration of the MSC-S platform are of interest to investors and competitors in the ophthalmology space. The company's focus on orphan diseases aligns with a growing trend in the industry.

Comparison to Industry Standards

• KALA BIO's focus on mesenchymal stem cell secretome (MSC-S) therapy is a relatively novel approach in the ophthalmology space, with few direct comparables.
• Companies like Aldeyra Therapeutics and Ocular Therapeutix are also developing therapies for ocular diseases, but their approaches differ from KALA's MSC-S platform.
• The $12.5 million private placement is a common funding strategy for clinical-stage biopharmaceutical companies, and the cash runway into 4Q 2025 is typical for companies at this stage of development.
• The reported net losses are consistent with the financial profile of a clinical-stage company that is investing heavily in research and development.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of clinical trials.
• Employees are impacted by the company's financial stability and research and development activities.
• Patients with rare and severe eye diseases may benefit from the development of new therapies.
• Investors are impacted by the company's financial performance and future prospects.

Next Steps

• KALA BIO will continue to enroll patients in the CHASE Phase 2b clinical trial.
• The company plans to report topline data from the CHASE trial in the first quarter of 2025.
• KALA BIO will continue to explore the potential of KPI-012 for additional rare eye diseases.
• The company will continue preclinical studies to evaluate the utility of its MSC-S platform for retinal degenerative diseases.

Key Dates

Keywords

KALA BIO, KPI-012, MSC-S platform, PCED, LSCD, Retinitis Pigmentosa, Stargardt Disease, Clinical Trials, Biopharmaceutical, Ocular Diseases, Private Placement, Financial Results